Clinical diagnostic lab company Artemis DNA — which provides next generation sequencing genetic and diagnostic testing — has received an accreditation from the College of American Pathologists (CAP) for its Irvine, California facility.
The College of American Pathologists advocates for excellence in the practice of pathology and laboratory medicine worldwide, and is recognized around the world for its established performance standards. Artemis DNA received its first accreditation from CAP for its facility in Houston, Texas.
“Receiving the CAP accreditation is a key milestone for us,” says Emylee Thai, founder and CEO of Artemis DNA.”This accreditation recognizes Artemis DNA’s continued commitment to maintaining the highest standards in the industry.”
The College of American Pathologists accreditation process is founded on a reciprocal and peer-based inspection methodology. The requirements are based on decades of experience in pathology, which are updated annually to reflect modern advances and technology.
Physical, on-site inspections are performed every two years as part of the accreditation process, with off-years requiring a self-inspection.
Artemis DNA is a full service, Clinical Laboratory Improvement Amendments (CLIA) certified, high-complexity clinical diagnostic laboratory company that provides proprietary Next Generation Sequencing (NGS) genetic testing and diagnostic laboratory services for a wide variety of medical specialties, including cardiology, oncology, immunology, neurology, reproductive health and pharmacogenomics.
